样式: 排序: IF: - GO 导出 标记为已读
-
Pearls and Pitfalls in the Measurement of Direct Oral Anticoagulants Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-03-08 Giuseppe Lippi, Emmanuel J. Favaloro
Due to their widespread use, testing for direct oral anticoagulants (DOACs) has become urgent in certain clinical situations. Screening based on widely available, rapid, and simple hemostasis assays such as prothrombin time, activated partial thromboplastin time, or even diluted Russel Viper venom time may provide sufficient evidence of “over-coagulation” and could be used “in small/peripheral/spoke
-
Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-03-01 Sina Rashedi, Christie M. Greason, Parham Sadeghipour, Azita H. Talasaz, Michelle L. O'Donoghue, David Jimenez, Manuel Monreal, Christopher D. Anderson, Mitchell S. V. Elkind, Lisa M. Baumann Kreuziger, Irene M. Lang, Samuel Z. Goldhaber, Stavros V. Konstantinides, Gregory Piazza, Harlan M. Krumholz, Eugene Braunwald, Behnood Bikdeli
Fibrinolytic agents catalyze the conversion of the inactive proenzyme plasminogen into the active protease plasmin, degrading fibrin within the thrombus and recanalizing occluded vessels. The history of these medications dates to the discovery of the first fibrinolytic compound, streptokinase, from bacterial cultures in 1933. Over time, researchers identified two other plasminogen activators in human
-
Variable Performance of D-dimer Testing by Hemostasis Laboratories: The Australasian/Asia-Pacific Experience Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-03-01 Emmanuel J. Favaloro, Sandya Arunachalam, Elysse Dean
D-dimers represent the breakdown products of fibrin. Thus, elevated plasma D-dimers will arise following a thrombotic event, such as a deep vein thrombosis or a pulmonary embolism, and therefore, a nonelevated D-dimer is used to effectively exclude such events. D-dimers are also elevated in a range of other conditions, for example, during disseminated intravascular coagulation. D-dimer levels may also
-
Lupus Anticoagulant-Hypoprothrombinemia Syndrome: Literature Review and Description of Local Case in a 3-Year-Old Chinese Girl Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-23 Bin Wang, Ning Tang, Chi Zhang
Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare, acquired coagulopathy syndrome. Here, we aim to summarize the clinical features of LAHPS to improve the understanding of the disease. The clinical data of 52 patients with LAHPS retrieved through PubMed from 2019 to 2023, supplemented with a local case of a child with LAHPS, were retrospectively analyzed, and the clinical characteristics
-
Venous Thrombosis in Airborne Viral Infections: Is Coronavirus Disease 2019 now Any Different from Influenza? Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-23 Giuseppe Lippi, Emmanuel J. Favaloro, Riccardo Nocini
One of the hallmarks of coronavirus disease 2019 (COVID-19), particularly in complicated cases (i.e., requiring hospitalization or intensive care support), is persistent hemostasis activation, which may be associated with a vast array of thrombotic episodes involving both the arterial and venous systems. The renewed emphasis on the relationship between viral infections and venous thrombosis paves the
-
Innovative Therapies for Acquired Hemophilia A Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-23 Massimo Franchini, Daniele Focosi
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder which can be life-threatening. AHA is due to autoantibodies against coagulation factor VIII. Disease onset may be idiopathic (approximately half of the cases) or triggered by autoimmune disorders, cancers, drugs, infections, or pregnancy. Besides treating the underlying disorder, specific AHA treatments include management of bleeding
-
Fibrinolysis-Mediated Pathways in Acute Liver Injury Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-23 Gina E. Capece, James P. Luyendyk, Lauren G. Poole
Acute liver injury (ALI), that is, the development of reduced liver function in patients without preexisting liver disease, can result from a wide range of causes, such as viral or bacterial infection, autoimmune disease, or adverse reaction to prescription and over-the-counter medications. ALI patients present with a complex coagulopathy, characterized by both hypercoagulable and hypocoagulable features
-
Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-23 Marissa B. Betts, Xuejun Liu, Daniela R. Junqueira, Kyle Fahrbach, Binod Neupane, Sarah Ronnebaum, Amol D. Dhamane
Patients with cancer have an increased risk of venous thromboembolism (VTE). Comparing tumor-specific VTE risk is complicated by factors such as surgery, disease stage, and chemotherapy. Network meta-analysis (NMA) using cancer types as network nodes enabled us to estimate VTE rates by leveraging comparisons across cancer types while adjusting for baseline VTE risk in individual studies. This study
-
Development of a Coagulation Disorders Unit Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-19 Timea Szanto, Tuukka Helin, Lotta Joutsi-Korhonen, Anna-Elina Lehtinen, Nancy El Beayni, Aino Lepäntalo, Riitta Lassila
Our Coagulation Disorders Unit in Helsinki, Finland, provides 24/7 services for local and national hospitals and colleagues upon requests regarding bleeding and thrombosis diagnostics and management, including follow-up. The unit has a tight connection between the clinic and laboratory, and its maintenance and sharing knowledge and observations have been priorities, already for over 20 years and will
-
The History of Diagnosing Venous Thromboembolism Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-19 Emily S.L. Martens, Menno V. Huisman, Thijs E. van Mens, Frederikus A. Klok
An accurate and prompt diagnosis of deep vein thrombosis and/or pulmonary embolism is important to prevent serious complications and mortality. Because the clinical presentation of venous thromboembolism (VTE) is often nonspecific, objective testing by means of radiological imaging is required to confirm the diagnosis. Historically, a diagnosis of VTE involved invasive imaging techniques like contrast
-
Tranexamic Acid: An Evergreen Hemostatic Agent Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-09
Tranexamic acid (TXA) is an important antifibrinolytic agent, which inhibits plasminogen activation and fibrinolysis. Several controlled randomized trials have investigated the role of TXA in preventing or decreasing blood loss across different surgical interventions or medical conditions characterized by excessive bleeding, consistently documenting its effectiveness and safety. Although the first
-
Progress in von Willebrand Disease Treatment: Evolution towards Newer Therapies Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-02-08 Miriam M. Moser, Christian Schoergenhofer, Bernd Jilma
von Willebrand disease (VWD) is a very heterogenous disease, resulting in different phenotypes and different degrees of bleeding severity. Established therapies (i.e., desmopressin, antifibrinolytic agents, hormone therapy for heavy menstrual bleeding, and von Willebrand factor [VWF] concentrates) may work in some subtypes, but not in all patients. In recent years, progress has been made in improving
-
Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-01-16 Rodrigo Aguirre del-Pino, Rory C. Monahan, Tom W.J. Huizinga, Jeroen Eikenboom, Gerda M. Steup-Beekman
Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple
-
Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-01-15 Rubhan Chandran, Eusni R. Mohd. Tohit, Johnson Stanslas, Norazlinaliza Salim, Tuan M.T. Mahmood, Mogana Rajagopal
The management of hemophilia A has undergone a remarkable revolution, in line with technological advancement. In the recent past, the primary concern associated with Factor VIII (FVIII) concentrates was the risk of infections, which is now almost resolved by advanced blood screening and viral inactivation methods. Improving patients' compliance with prophylaxis has become a key focus, as it can lead
-
Venous Thromboembolism in Children: The Rivaroxaban Experience Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-01-05 Luca Spiezia, Elena Campello, Daniela Tormene, Paolo Simioni
The incidence of venous thromboembolism (VTE) in the pediatric population has increased more than 10-fold in the last 20 years, as a consequence of the advancement of resuscitation and surgical techniques and the global increase in life expectancy of children suffering from chronic pathologies. Monitoring anticoagulant therapy to achieve outcomes within the target range in childhood VTE, parenteral
-
Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2024-01-04 Behnood Bikdeli, Parham Sadeghipour, Junyang Lou, Antoine Bejjani, Candrika D. Khairani, Sina Rashedi, Robert Lookstein, Alexandra Lansky, Suresh Vedantham, Piotr Sobieszczyk, Carlos Mena-Hurtado, Ayaz Aghayev, Peter Henke, Ghazaleh Mehdipoor, Antonella Tufano, Saurav Chatterjee, Saskia Middeldorp, Suman Wasan, Riyaz Bashir, Irene M. Lang, Mehdi H. Shishehbor, Marie Gerhard-Herman, Jay Giri, Matthew
The inferior vena cava (IVC) and superior vena cava are the main conduits of the systemic venous circulation into the right atrium. Developmental or procedural interruptions of vena cava might predispose to stasis and deep vein thrombosis (DVT) distal to the anomaly and may impact the subsequent rate of pulmonary embolism (PE). This study aimed to review the various etiologies of developmental or procedural
-
Blood Rheology and Hemodynamics Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-12-20 Oguz K. Baskurt, Herbert J. Meiselman
Seminars in Thrombosis and Hemostasis (STH) celebrates 50 years of publishing in 2024. To celebrate this landmark event, STH is republishing some archival material. This manuscript represents the most highly cited paper ever published in STH. The original abstract follows. Blood is a two-phase suspension of formed elements (i.e., red blood cells [RBCs], white blood cells [WBCs], platelets) suspended
-
PFA-100 System: A New Method for Assessment of Platelet Dysfunction Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-12-13
This is a celebratory reprint of a historical paper published in STH in 1998. The original Abstract follows.The PFA-100 system is a platelet function analyzer designed to measure platelet-related primary hemostasis. The instrument uses two disposable cartridges: a collagen/epinephrine (CEPI) and a collagen/ADP (CADP) cartridge. Previous experience has shown that CEPI cartridges detect qualitative platelet
-
A Critical Reappraisal of the Bleeding Time Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-12-12
Seminars in Thrombosis and Hemostasis (STH) celebrates 50 years of publishing in 2024. To celebrate this landmark event, STH is republishing some archival material. This manuscript represents the second most highly cited paper ever published in STH. The manuscript published without an abstract, and essentially represented a State of the Art Review on the bleeding time, a relatively invasive procedure
-
Description of an In Vitro Platelet Function Analyzer—PFA-100™ Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-12-12 Sourav K. Kundu, Eric J. Heilmann, Reynaldo Sio, Carmen Garcia, Rosa M. Davidson, Roy A. Ostgaard
This manuscript represents a republication of a manuscript originally published in STH in 1995. This republication is to help celebrate 50 years of publishing for STH. The original abstract follows. A new in vitro system for the detection of platelet dysfunction, PFA-100®, has been developed. It provides a quantitative measure of platelet function in anticoagulated whole blood. The system comprises
-
Platelets: Physiology and Biochemistry Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-12-12 Kerstin Jurk, Beate E. Kehrel
This manuscript represents a republication of a manuscript originally published in STH in 2005. This republication is to help celebrate 50 years of publishing for STH. The original abstract follows. Platelets are specialized blood cells that play central roles in physiologic and pathologic processes of hemostasis, inflammation, tumor metastasis, wound healing, and host defense. Activation of platelets
-
Cellular Components Contributing to the Development of Venous Thrombosis in Patients with Pancreatic Cancer Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-12-04 Ruth Anne Laura Willems, Charlotte Biesmans, Elena Campello, Paolo Simioni, Bas de Laat, Judith de Vos-Geelen, Mark Roest, Hugo ten Cate
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer and has a poor prognosis. Patients with PDAC are at high risk of developing thromboembolic events, which is a leading cause of morbidity and mortality following cancer progression. Plasma-derived coagulation is the most studied process in cancer-associated thrombosis. Other blood components, such as platelets, red blood cells,
-
Dosing, Monitoring, Blood Product Utilization, and Thromboembolic Complications of Four-Factor Prothrombin Complex Concentrate as Part of an Institutional Protocol in Pediatric Cardiac Surgery: A Retrospective Cohort Study Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-12-04 Amy L. Kiskaddon, Neil A. Goldenberg, Jamie L. Fierstein, Alexandra Miller, James A. Quintessenza, Vyas M. Kartha
Pediatric cardiac surgery patients are predisposed to blood loss. Blood product administration can lead to complications. Prothrombin complex concentrates (PCCs) offer potential advantages of factor composition, small volume, decreased immunogenicity/infectious risks, and accessibility. The objective of this study was to describe dosing, monitoring, blood product utilization, and thromboembolic complications
-
Disseminated Intravascular Coagulation in Anaphylaxis Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-29 Georg Gelbenegger, Nina Buchtele, Christian Schoergenhofer, Jürgen Grafeneder, Michael Schwameis, Peter Schellongowski, Wolfgang Denk, Bernd Jilma
Anaphylaxis is a life-threatening condition that involves severe cutaneous, respiratory, and cardiovascular symptoms. Disseminated intravascular coagulation (DIC) is an acquired, widespread activation of coagulation that can be caused by infectious conditions (e.g., sepsis) and noninfectious conditions. The onset of DIC following anaphylaxis is not commonly known, and information regarding the pathomechanism
-
Bleeding Scoring Systems in Neonates: A Systematic Review Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-28 Rozeta Sokou, Stavroula Parastatidou, Aikaterini Konstantinidi, Andreas G. Tsantes, Nicoletta Iacovidou, Daniele Piovani, Stefanos Bonovas, Argirios E. Tsantes
We conducted a systematic review aiming to summarize the data on the current hemorrhage prediction models and evaluate their potential for generalized application in the neonatal population. The electronic databases PubMed and Scopus were searched, up to September 20, 2023, for studies that focused on development and/or validation of a prediction model for bleeding risk in neonates, and described the
-
Role of Platelets in Rheumatic Chronic Autoimmune Inflammatory Diseases Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-28 Martin Jozef Péč, Jakub Jurica, Monika Péčová, Jakub Benko, Juraj Sokol, Tomáš Bolek, Marek Samec, Tatiana Hurtová, Peter Galajda, Matej Samoš, Marián Mokáň
Platelets are essential in maintaining blood homeostasis and regulating several inflammatory processes. They constantly interact with immune cells, have immunoregulatory functions, and can affect, through immunologically active substances, endothelium, leukocytes, and other immune response components. In reverse, inflammatory and immune processes can activate platelets, which might be significant in
-
The Molecular Structure of Fibrinogen Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-24 Genesio Murano
Seminars in Thrombosis and Hemostasis (STH) celebrates 50 years of publishing in 2024. To celebrate this landmark event, STH is republishing some archival material. This manuscript represents the first full paper ever published in STH. The manuscript published without an abstract, and essentially covered in considerable detail the molecular structure of fibrinogen, as was known at that time. Fittingly
-
The Complex Role of Thrombin in Cancer and Metastasis: Focus on Interactions with the Immune System Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-20
Thrombin, a pleiotropic enzyme involved in coagulation, plays a crucial role in both procoagulant and anticoagulant pathways. Thrombin converts fibrinogen into fibrin, initiates platelet activation, and promotes clot formation. Thrombin also activates anticoagulant pathways, indirectly inhibiting factors involved in coagulation. Tissue factor triggers thrombin generation, and the overexpression of
-
Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-20 Massimo Franchini,Arturo Casadevall,Jonathon W Senefeld,Michael J Joyner,David J Sullivan,Daniele Focosi
-
International Council for Standardization in Haematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-15 Robert C. Gosselin, Donna Castellone, Akbar Dorgalaleh, Kieron Hickey, Giuseppe Lippi, Karen Moffat, Rebecca O'Toole, Joe Rigano
The clinical laboratory uses commercial products with limited shelf life or certain expiry dates requiring frequent lot changes. Prior to implementation for clinical use, laboratories should determine the performance of the new reagent lot to ensure that there is no significant shift in reagent performance or reporting of patient data. This guideline has been written on behalf of the International
-
Variable Performance of Lupus Anticoagulant Testing: The Australasian/Asia-Pacific Experience Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-15 Emmanuel J. Favaloro, Elysse Dean, Sandya Arunachalam
Lupus anticoagulant (LA) is one of three tests identified as laboratory criteria for definite antiphospholipid syndrome (APS). The other two tests are anticardiolipin antibody (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibody. The presence of LA is assessed using clot-based tests, while the presence of aCL and aβ2GPI is assessed by immunological assays. Since no test can be considered 100% sensitive
-
The Bleeding Time Test in 2024: A Glorious Past and Current Challenges. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-11-15 Anetta Undas
-
Description of an In Vitro Platelet Function Analyzer (PFA-100/PFA-200) 30 Years in the Making. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-30 Emmanuel J Favaloro
-
Classification Criteria for the Antiphospholipid Syndrome: Not the Same as Diagnostic Criteria for Antiphospholipid Syndrome. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-20 Emmanuel J Favaloro,Leonardo Pasalic,Giuseppe Lippi
-
In Search of the Perfect Thrombosis and Bleeding-Associated Cancer Scale Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-18
Thrombosis and bleeding are commonly observed in cancer patients, and their management is crucial for positive patient outcomes. A comprehensive, prophylactic, and therapeutic management of venous thrombosis should focus on identifying the patients who would benefit most from treatment to reduce mortality and minimize the risk of thrombosis recurrence without significantly increasing the risk of bleeding
-
Platelet Contributions to the (Pre)metastatic Tumor Microenvironment Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-13 Harvey G. Roweth
Alongside their conventional roles in thrombosis and hemostasis, platelets have long been associated with nonhemostatic pathologies, including tumor cell metastasis. Numerous mechanistic studies have since demonstrated that the direct binding of platelets to intravascular tumor cells promotes key hallmarks of metastasis, including survival in circulation and tumor cell arrest at secondary sites. However
-
Trends (2020–2022) toward Reduced Prevalence of Postcoronavirus Disease Syndrome and Improved Quality of Life for Hospitalized Coronavirus Disease 2019 Patients with Severe Infection and Venous Thromboembolism Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-13 Antonio Bozzani, Vittorio Arici, Guido Tavazzi, Franco Ragni, Francesco Mojoli, Elena Cavallini, Floris van Vugt, Sara Cutti, Silvia Figini, Alessandro Venturi, Antonio V. Sterpetti, Eloisa Arbustini
The coronavirus disease 2019 (COVID-19) pandemic seems to be at its end. During the first outbreak, alfa was the dominant variant, and in the two following years, delta was the dominant variant. Questions remain about the prevalence and severity of post-COVID syndrome (PCS). We compared the medium-term outcomes of a selected group of patients considered at high risk for PCS: hospitalized patients with
-
The Diagnostic Role of Lung Ultrasound and Contrast-Enhanced Ultrasound in Pulmonary Embolism Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-13 Andrea Boccatonda, Lorenzo Andreetto, Susanna Vicari, Elena Campello, Paolo Simioni, Walter Ageno
The diagnosis of pulmonary embolism (PE) relies essentially on a probabilistic approach that requires careful clinical assessments, targeted laboratory tests, and the use of appropriate imaging tools. Nowadays, the diagnostic gold standard is computed tomographic pulmonary angiography. Lung ultrasound (LUS) can play a role in the diagnosis of PE mainly by allowing the visualization of peripheral lung
-
Optimizing and Extending the Risk-Adapted Management of Acute Pulmonary Embolism beyond the Acute Phase: Progress in Pulmonary Embolism Research. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-13 Stefano Barco,Frederikus A Klok,Behnood Bikdeli
-
Thrombin Generation Markers as Predictors of Cancer-Associated Venous Thromboembolism: A Systematic Review Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-09 Tua Gyldenholm, Anne-Mette Hvas, Thomas Decker Christensen, Julie Brogaard Larsen
Venous thromboembolism (VTE) is a main contributor to morbidity and mortality in cancer patients. Biomarkers with the potential to predict cancer-associated VTE are continually sought. Of these, markers of thrombin generation present a likely option. The present systematic review examines the ability of three widely used biomarkers of thrombin generation: prothrombin fragment 1.2 (F1.2), thrombin-antithrombin
-
Whole Blood Viscosity and Cerebral Blood Flow in Acute Ischemic Stroke Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-09 Prajwal Gyawali, Thomas P. Lillicrap, Carlos G. Esperon, Aseem Bhattarai, Andrew Bivard, Neil Spratt
Existing effective treatments for ischemic stroke restore blood supply to the ischemic region using thrombolysis or mechanical removal of clot. However, it is increasingly recognized that successful removal of occlusive thrombus from the large artery—recanalization, may not always be accompanied by successful restoration of blood flow to the downstream tissues—reperfusion. Ultimately, brain tissue
-
Fifty Years of Fibrinogen Structure and Function. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-10-09 Marguerite Neerman-Arbez,Alessandro Casini
-
Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-09-27 Akbar Dorgalaleh, Seyed Mehrab Safdari, Shadi Tabibian, Mahmood Shams, Ali Dabbagh, Azadeh Rezazadeh
Hypercoagulability is a prominent feature of coronavirus disease 2019 (COVID-19) and can lead to fatal consequences. Although the impact of COVID-19 on several disorders is well-established, its effect on congenital bleeding disorders (CBDs) is not well-documented. To address this ambiguity, a systematic review was conducted on the available studies to determine the impact of COVID-19 and vaccination
-
ABO Blood Group and the Risk of Thrombosis in Cancer Patients: A Mini-Review Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-09-26 Salah Elsherif, Ali Zidan, Olivia Saville, Maha Othman
Cancer-associated thrombosis (CT), especially venous thromboembolism (VTE), is a common occurrence with several factors contributing to a wide diversity in thrombosis risk. The association between ABO blood groups and the risk for CT has been examined in various studies, with non-O blood type associated with an increased thrombosis risk; however, these studies have reported varying results with recognized
-
The Most Highly Cited Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 50 Years in the Making. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-09-27 Emmanuel J Favaloro
-
Internal Quality Control in Hemostasis Assays Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-09-25 Christopher Reilly-Stitt, Ian Jennings, Steve Kitchen, Isobel D. Walker
Internal quality control (IQC) for routine and specialist hemostasis testing represents a mandatory requirement for assays offered by clinical laboratories under International Organization for Standardization, Code of Federal Regulations, and Clinical and Laboratory Standards Institute standards. The underlying principle is that regular IQC audits the analytical performance of automated, semiautomated
-
What Role Does Microthrombosis Play in Long COVID? Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-09-25 Toshiaki Iba, Jean M. Connors, Jerrold H. Levy
Soon after the outbreak of coronavirus disease 2019 (COVID-19), unexplained sustained fatigue, cognitive disturbance, and muscle ache/weakness were reported in patients who had recovered from acute COVID-19 infection. This abnormal condition has been recognized as “long COVID (postacute sequelae of COVID-19 [PASC])” with a prevalence estimated to be from 10 to 20% of convalescent patients. Although
-
A Perspective on How Fibrinaloid Microclots and Platelet Pathology May be Applied in Clinical Investigations Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-09-25 Etheresia Pretorius, Douglas B. Kell
Microscopy imaging has enabled us to establish the presence of fibrin(ogen) amyloid (fibrinaloid) microclots in a range of chronic, inflammatory diseases. Microclots may also be induced by a variety of purified substances, often at very low concentrations. These molecules include bacterial inflammagens, serum amyloid A, and the S1 spike protein of severe acute respiratory syndrome coronavirus 2. Here
-
A Novel Variant on the Thrombospondin Type-1 Repeat 2 Domain of ADAMTS13 in a Parturient with Suspected Hereditary Thrombotic Thrombocytopenic Purpura and Unusually High ADAMTS13 Activity. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-09-19 Junkun Chen,Ning Tang,Xiong Wang,Jiaoyuan Li
-
Advanced Treatment of Hemodynamically Unstable Acute Pulmonary Embolism and Clinical Follow-up Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-09-11 Brian Fulton, Riyaz Bashir, Mitchell D. Weinberg, Vladimir Lakhter, Parth Rali, Steve Pugliese, Jay Giri, Taisei Kobayashi
High-risk acute pulmonary embolism (PE), defined as acute PE associated with hemodynamic instability, remains a significant contributor to cardiovascular morbidity and mortality in the United States and worldwide. Historically, anticoagulant therapy in addition to systemic thrombolysis has been the mainstays of medical therapy for the majority of patients with high-risk PE. In efforts to reduce the
-
Anticoagulation with Intravenous Direct Thrombin Inhibitors in Pediatric Extracorporeal Membrane Oxygenation: A Systematic Review of the Literature Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-08-29 Amy L. Kiskaddon, Nhue L. Do, Pamela Williams, Marisol Betensky, Neil A. Goldenberg
Although intravenous (IV) direct thrombin inhibitors (DTI) have gained interest in pediatric extracorporeal membrane oxygenation (ECMO), dosing and safety information is limited. The objective of this systematic review was to characterize DTI types, dosing, monitoring, and outcomes (bleeding and thromboembolic) in pediatric ECMO patients managed with IV DTIs. We conducted searches of MEDLINE (Ovid)
-
Detecting Oxygenator Thrombosis in ECMO: A Review of Current Techniques and an Exploration of Future Directions Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-08-28 Jack Leerson, Andrew Tulloh, Francisco Tovar Lopez, Shaun Gregory, Hergen Buscher, Gary Rosengarten
Extracorporeal membrane oxygenation (ECMO) is a life-support technique used to treat cardiac and pulmonary failure, including severe cases of COVID-19 (coronavirus disease 2019) involving acute respiratory distress syndrome. Blood clot formation in the circuit is one of the most common complications in ECMO, having potentially harmful and even fatal consequences. It is therefore essential to regularly
-
Same Syndrome, Different Causes and Treatment: Path to Diagnosis and Management of Two Interesting Cases of Acquired von Willebrand Syndrome. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-08-28 Marta Monti,Evita Massari,Marco Rosetti,Alice Clementoni,Giovanni Poletti,Melania Olivieri,Daniela Conti,Tommaso Fasano
-
Welcome to Seminars in Thrombosis and Hemostasis 2024: 50 Years of Publishing. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-08-28 Emmanuel J Favaloro
-
Association of Circulating Long Noncoding 7S RNA with Deep Vein Thrombosis Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-08-23 Xiao Wang, Ashfaque A. Memon, Anna Hedelius, Anton Grundberg, Johan L. Elf, Peter J. Svensson, Jan Sundquist, Kristina Sundquist
Mitochondrial dysfunction is a recognized factor in the pathogenesis of deep vein thrombosis (DVT). The role of 7S RNA, a long noncoding RNA that plays an important role in mitochondrial function, in DVT remains unclear. In this study, we aimed to investigate the potential use of 7S RNA as a biomarker in DVT. Plasma samples were obtained from 237 patients (aged 16–95 years) with suspected DVT recruited
-
Laser-Induced Blood Coagulation for Surgical Application: A Scoping Review Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-08-23 Afnan Sedky Adly, Mahmoud Sedky Adly, Frederic Cuisinier, Jean-Christophe Egea, Ivan Panayotov, Aya Sedky Adly, Eve Malthiery
There is a lack of evidence-based reviews on the effects of laser irradiation on blood coagulation in the literature, despite a large number of clinical trials. We therefore evaluated the available evidence on laser irradiation parameters used in coagulation of blood to optimize physical parameters. We performed a literature search for recent scientific studies indexed between 2017 and 2023 using the
-
Safety and Efficacy of Therapeutic Anticoagulation with Subcutaneous Unfractionated Heparin in Patients with Renal Failure. Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-08-23 Giulia Simini,Frances Akor,Richard Szydlo,Michael Laffan,Deepa R J Arachchillage
-
In Search of the Holy Grail of Artificial Hearts: Are We There Yet? Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-08-21 Oksana Volod, Modesto J. Colon, Francisco A. Arabía
The total artificial heart (TAH) has a long and rich history, being the product of decades of innovation, hard work, and dedication. This review examines the history of the TAH, a device that has revolutionized the treatment of end-stage biventricular heart failure. It reviews the development of the device from early concepts to the current state-of-the-art device, the SynCardia TAH, which has been
-
Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-07-28 Gianluca Costamagna, Babak B. Navi, Morin Beyeler, Andreas F. Hottinger, Lorenzo Alberio, Patrik Michel
Ischemic stroke is an important cause of morbidity and mortality in cancer patients. The underlying mechanisms linking cancer and stroke are not completely understood. Long-standing and more recent evidence suggests that cancer-associated prothrombotic states, along with treatment-related vascular toxicity, such as with chemotherapy and immunotherapy, contribute to an increased risk of ischemic stroke
-
Russell Viper Venom: A Journey from the Bedside to the Bench and Back to the Bedside Semin. Thromb. Hemost. (IF 5.7) Pub Date : 2023-07-28 Jecko Thachil
Russel Viper Venom (RVV) is widely used as a diagnostic test for antiphospholipid syndrome (APS). But the history of how this venom came to be discovered is well known. Dr Patrick Russel is responsible for the identification of the venom during his work on snake bites in India while Dr Robert Macfarlane used it to staunch bleeding in persons with haemophilia. The ability to directly activate factor